LifeVantage Corporation (LFVN) is a Healthcare stock trading at $6.66 (as of 2026-08-21), with a market capitalization of $84.02M and a trailing P/E of 11.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.
LifeVantage sells nutrigenomic activators and dietary supplements, including Protandim and Liquid Collagen products, and makes money from the sale and distribution of these targeted health brands.
Repeat buying in Liquid Collagen appears central to the profit model, with a high Second Month Reorder Rate (77.8%) alongside Liquid Collagen penetration through the consultant and distributor channels.
| Americas | $0.0B |
| APAC+Europe | $0.0B |
Business quality (Weak): The profit model narrative is most supported by Liquid Collagen operating metrics (reorder and penetration rates). Segment revenue detail provided is mainly by region, and overall revenue is extremely small in the dataset, which limits how much can be concluded about other product lines.
Valuation: At 14× earnings, LFVN trades 15% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $6.66 |
| Market Cap | $84.02M |
| P/E Ratio | 11.6 |
| EV / EBITDA | 4.8 |
| Price / Book | 2.52 |
| Price / Sales | 0.42 |
| FCF Yield | 10.5% |
| DCF Value (model) | $41.82 |
| DCF Upside vs Price | 527.9% |
| Revenue (TTM) | $228.53M |
| Net Margin | 4.3% |
| Revenue Growth (YoY) | -25.2% |
| EPS Growth (YoY) | -60.7% |
| FCF Growth (YoY) | -69.6% |
| Altman Z-Score | 3.46 (safe) |
| Stock P/E | 11.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -46.6% |
| vs Industry | -31.8% |
| Top Institutional Holder | CAPITAL MANAGEMENT CORP /VA ($10.55M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Steven R. Fife |
| Employees | 222 |
| Country | US |
| IPO Date | 1994-04-07 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.